IO Biotech, Inc. financial data

Symbol
IOBT on Nasdaq
Industry
Pharmaceutical Preparations
Location
Ole Maaloes Veh 3, Copenhagen, Denmark
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 823 % -34.2%
Debt-to-equity 15.1 % +47.5%
Return On Equity -86.6 % -42.1%
Return On Assets -75.3 % -36.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9M shares 0%
Common Stock, Shares, Outstanding 65.9M shares 0%
Entity Public Float 31.1M USD -57.5%
Common Stock, Value, Issued 66K USD 0%
Weighted Average Number of Shares Outstanding, Basic 65.9M shares +31.3%
Weighted Average Number of Shares Outstanding, Diluted 65.9M shares +31.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 72.1M USD +19.2%
General and Administrative Expense 24.3M USD +4.98%
Operating Income (Loss) -96.4M USD -15.3%
Nonoperating Income (Expense) 7.43M USD +43.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -89M USD -13.4%
Income Tax Expense (Benefit) 1.35M USD -9.15%
Net Income (Loss) Attributable to Parent -90.4M USD -13%
Earnings Per Share, Basic -1.19 USD/shares +51.6%
Earnings Per Share, Diluted -1.19 USD/shares +51.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 80.2M USD -51.6%
Assets, Current 86.2M USD -48.7%
Property, Plant and Equipment, Net 695K USD -12.8%
Operating Lease, Right-of-Use Asset 1.81M USD -23.4%
Other Assets, Noncurrent 924K USD +6.57%
Assets 89.9M USD -47.9%
Accounts Payable, Current 5.26M USD -20.9%
Employee-related Liabilities, Current 3.56M USD +31.7%
Liabilities, Current 16.1M USD +23.6%
Operating Lease, Liability, Noncurrent 1.33M USD -32.9%
Liabilities 17.4M USD +16.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -11M USD -11.4%
Retained Earnings (Accumulated Deficit) -328M USD -38%
Stockholders' Equity Attributable to Parent 72.6M USD -54%
Liabilities and Equity 89.9M USD -47.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.9M USD -69.7%
Net Cash Provided by (Used in) Investing Activities -11K USD +92.6%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.9M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 151M USD +233%
Deferred Tax Assets, Valuation Allowance 57.9M USD +65.5%
Deferred Tax Assets, Gross 58.4M USD +64.2%
Depreciation 62K USD +31.9%
Payments to Acquire Property, Plant, and Equipment 11K USD -92.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -91.5M USD -20.5%
Lessee, Operating Lease, Liability, to be Paid 2.21M USD -24.8%
Operating Lease, Liability, Current 694K USD +10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 802K USD +2.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 796K USD +1.79%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 406K USD -48.5%
Deferred Tax Assets, Operating Loss Carryforwards 50.3M USD +60.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 193K USD +10.3%
Additional Paid in Capital 411M USD +1.59%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 250K USD -26.5%
Deferred Tax Assets, Net of Valuation Allowance 479K USD -17.6%
Share-based Payment Arrangement, Expense 6.45M USD -21%
Interest Expense 302K USD -16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%